Friday, March 31, 2023
WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.
Clinical Lead
UCLH Centre for Waldenström’s Macroglobulinemia
Consultant Hematologist and Associate Professor
Department of Hematology at UCL NHS Foundation Trust
London, United Kingdom
Professor of Hematology
Department of Clinical Oncology
Maria Skłodowska-Curie National Research Institute of Oncology
Krakow, Poland
Clinical Nurse Specialist
Myeloma and Plasma Cell Disorders
UCLH
London, United Kingdom
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This educational activity is intended for a global audience of healthcare professionals, specifically hematology/oncology specialists and pathologists, and any other healthcare specialists involved in the care of patients with B-cell malignancies.
The goal of this activity is to improve physician knowledge and competence regarding effective management strategies for treatment-related side effects associated with first- and next-generation Bruton tyrosine kinase (BTK) inhibitors for B-cell malignancies.
Upon completion of this activity, participants will:
WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.
Clinical Lead
UCLH Centre for Waldenström’s Macroglobulinemia
Consultant Hematologist and Associate Professor
Department of Hematology at UCL NHS Foundation Trust
London, United Kingdom
Professor of Hematology
Department of Clinical Oncology
Maria Skłodowska-Curie National Research Institute of Oncology
Krakow, Poland
Clinical Nurse Specialist
Myeloma and Plasma Cell Disorders
UCLH
London, United Kingdom
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.5 continuing professional development credits (CPD).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim
credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online
during the credit
eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied
in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well
as the certificates by
accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CPD Released: 1/5/2022
Valid for credit through: 1/5/2023
processing....
A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.
